Heron Therapeutics Inc (HRTX) Implied Volatility Current

Tracking HRTX implied volatility helps you identify when options premiums on Heron Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Heron Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when HRTX IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Heron Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For HRTX, tracking metrics like HRTX IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on HRTX signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where HRTX implied volatility sits today versus where it has been. Our scanner ranks Heron Therapeutics Inc implied volatility against its historical range, surfaces extremes in HRTX IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Heron Therapeutics Inc IV is rich or cheap — measure it, then act on it.